Sutro Biopharma Inc logo

STRO

Sutro Biopharma Inc

$6.64

Earnings Summary

Revenue
$5.9Mn
Net Profits
$-39.11Mn
Net Profit Margins
-663.22%

Highlights

Revenue:

Sutro Biopharma Inc’s revenue fell -59.77% since last year same period to $5.9Mn in the Q1 2022. On a quarterly growth basis, Sutro Biopharma Inc has generated -44.65% fall in its revenue since last 3-months.

Net Profits:

Sutro Biopharma Inc’s net profit fell -28.83% since last year same period to $-39.11Mn in the Q1 2022. On a quarterly growth basis, Sutro Biopharma Inc has generated -2.58% fall in its net profits since last 3-months.

Net Profit Margins:

Sutro Biopharma Inc’s net profit margin fell -220.26% since last year same period to -663.22% in the Q1 2022. On a quarterly growth basis, Sutro Biopharma Inc has generated -85.34% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Sutro Biopharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.46
EPS Estimate Current Year
-0.46

Highlights

EPS Estimate Current Quarter:

Sutro Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.46 - a 39.47% jump from last quarter’s estimates.

EPS Estimate Current Year:

Sutro Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.46.

Key Ratios

Key ratios of the Sutro Biopharma Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.84
Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.36
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Sutro Biopharma Inc’s earning per share (EPS) fell -27.27% since last year same period to -0.84 in the Q1 2022. This indicates that the Sutro Biopharma Inc has generated -27.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sutro Biopharma Inc’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sutro Biopharma Inc’s return on equity (ROE) stands at -0.36.

Dividend Per Share (DPS):

Sutro Biopharma Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.76
-0.84
-10.53%

Company Information

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Organisation
Sutro Biopharma Inc
Headquarters
South San Francisco, California, US
Employees
192
Industry
Health Technology
CEO
William Newell